Skip to main content
OpenTrials
Completed

NCT Number: NCT02425735

Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

In this study, effects of γδT cells on human hepatocellular liver cancer in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Cancer Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Biological treatment center in Fuda cancer hospital

Guangzhou, Guangdong, 510000, China

About this study

Liver tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age:18-75
  • Karnofsky performance status >50
  • Diagnosis with hepatocellular carcinoma cancer based on histology or the current accepted radiological measures.
  • Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ
  • Will receive cryosurgery, gd Tcells/ DC-CIK.
  • Life expectancy: Greater than 3 months
  • Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion criteria

  • Patients with other kinds of cancer
  • History of coagulation disorders or anemia
  • Patients with heart disease and diabetes

Treatment and study plan

DC-CIK cells

Biological

DC-CIK cells will be used against tumor cells.

γδ T cells

Biological

γδ T cells will be used against breast tumor.

γδ T/DC-CIK cells

Biological

γδ T/DC-CIK cells will be used against breast tumor.

Primary outcomes

  1. Reduced size of the tumors

    Time frame: Up to one year

Sponsors and collaborators

Lead sponsor

Fuda Cancer Hospital, Guangzhou

Other

Collaborators

  • Jinan University Guangzhou

Registry information

Official study title

γδ T Cell Immunotherapy for Treatment of Hepatocellular Liver Cancer

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Apr 24, 2015
Registry last updated
Jul 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.